The SEC Pulse

ZAG-S&W Represents Therapix Biosciences in $13.8 Million Initial Public Offering

Posted by Leah Schloss on March 30, 2017 at 1:42 PM
Find me on:

Culminating a process that began last July, ZAG-S&W advised Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: THXBY) on its initial public offering of American Depositary Shares in the United States, which debuted on Nasdaq last week (and is still trading well above its initial price).

Image result for therapix

Therapix is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.  The company has initiated two internal drug development programs based on repurposing an FDA-approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of Tourette Syndrome, and BrainBright Pharma developing THX-ULD01 targeted to the treatment of mild cognitive impairments. 

Therapix raised a total of $13.8 million (including full exercise of the underwriters’ overallotment option), which it plans to use to advance the formulation and clinical development efforts for its two lead product candidates, including Phase II clinical trials, and for working capital and other general corporate purposes. Laidlaw & Company (UK) Ltd. acted as sole book running manager for the offering.

The ZAG-S&W team consisted of attorneys from Boston, New York and Tel Aviv, including Howard Berkenblit, Oded Har-Even and David Huberman, as well as Shy Baranov, Rob Condon, Ron Ben-Bassat, Boaz Shiffman and Hila Nahum.

Topics: NASDAQ, IPO, pharmaceuticals

About the Blog


The SEC Pulse provides updates and commentary from our Capital Markets Group on issues affecting publicly traded and privately owned businesses, investment banks and foreign companies who trade or raise capital in the United States, and boards of directors and company officers in securities transactions and corporate governance matters. 

Meet Howard Berkenblit, SEC Pulse editor

 

Learn more about our Capital Markets Group

 

View our Public Company Compliance Manual

JOBS-portal-click-to-view.jpg

Subscribe to Blog